West Pharmaceutical Services Issues Statement on Exubera
LIONVILLE, Pa., Oct. 18 /PRNewswire-FirstCall/ -- West Pharmaceutical
Services, Inc. (NYSE: WST ) today provided comments related to Pfizer,
Inc.'s announcement that it has decided to discontinue marketing the
Exubera Inhalable Insulin product, returning the marketing rights to the
New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
...56,321 61,832 207,254
Operating costs and expenses: Cost of goods sold 5,349 27,457 18,020 123,469 Cost of idle exubera
manufacturing capacity 6,821 Research and development 38,265 35,773 109,138 114,265 General...
West Announces Third Quarter 2008 Results
...or certain anemia, or ESA, drugs, the
inhalable insulin device, and certain disposable
particularly ESA components and exubera
devices, and to raw material and
other production ... Company's costs of maintaining and
converting the exubera
device production facility and related tangible
Nektar Therapeutics Announces Second Quarter 2008 Results
associated with Pfizer's termination of the exubera
maintenance of exubera
manufacturing capacity through April 2008. The fin...and charges associated with the termination of the exubera
insulin program were paid and recorded in ...
West Announces Second Quarter 2008 Results
...to the manufacture of
devices for the discontinued exubera
product, net of $1.4 million of
restructuring cost...ear period. Lower sales were due to
the absence of exubera
inhalable insulin device sales and of packaging fo...the Company's costs of maintaining and
closing the exubera
device production facility and of related tangible...
Nektar Therapeutics Announces First Quarter 2008 Results
...he first quarter of 2007. This decrease is the result of
the termination of exubera
"The first quarter was significant for Nektar as it represents...ds sold 7,227 56,522 Cost of idle exubera
manufacturing capacity 5,334 ...
Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
... 38,489 12,053 85,925 56,303 exubera
commercialization readiness ...87 40,100 137,696 113,921 Cost of idle exubera
manufacturing capacity 6,314 - 6,314 - exubera
commercialization readiness costs ...
Endocrinology Panel Examines Interplay Between Diabetes and Cardiovascular Disease in New Report
...ow each fits into the diabetes / CAD paradigm. -- The Panel describes why exubera
has failed commercially, and benchmarks next-generation insulins. -- ...Nordisk), Actos (pioglitazone; Takeda/Lilly),
Avandia (rosiglitazone; GSK), exubera
(Nektar), AIR Insulin
(Lilly/Alkermes), Technosphere (Mannkind), AERx (Novo...
MannKind Corporation Reports Third Quarter Financial Results
...y received $250 million in
gross proceeds from its self managed registered direct offering of
approximately 27 million shares of common stock. "While exubera
stumbled in the marketplace and then was ultimately
withdrawn, our Technosphere Insulin is very different and continues to be
well received by patient...